Comparing SG&A Expenses: Viking Therapeutics, Inc. vs ImmunityBio, Inc. Trends and Insights

Biotech Giants' SG&A Expenses: A Decade of Strategic Spending

__timestampImmunityBio, Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 201443260001244910
Thursday, January 1, 20152262060005029636
Friday, January 1, 2016943910004846776
Sunday, January 1, 2017538210005329003
Monday, January 1, 2018354630007121000
Tuesday, January 1, 2019464560009128000
Wednesday, January 1, 20207131800010731000
Friday, January 1, 202113525600010701000
Saturday, January 1, 202210270800016121000
Sunday, January 1, 202312962000037021000
Loading chart...

Infusing magic into the data realm

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of two prominent biotech firms: ImmunityBio, Inc. and Viking Therapeutics, Inc., from 2014 to 2023.

ImmunityBio, Inc. has seen a significant fluctuation in its SG&A expenses, peaking in 2015 with a staggering 2.26 billion, then stabilizing around 1.3 billion in recent years. This represents a 43% increase from its lowest point in 2018. In contrast, Viking Therapeutics, Inc. has maintained a more consistent trajectory, with expenses growing steadily from 1.2 million in 2014 to 37 million in 2023, marking a 29-fold increase.

These trends highlight the differing strategies and growth phases of these companies, offering valuable insights into their operational efficiencies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025